The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations
Open accessAbstract
RATIONALE: Reducing asthma exacerbation frequency is an important criterion for approval of asthma therapies, but the clinical features of exacerbation-prone asthma (EPA) remain incompletely defined. OBJECTIVES: To describe the clinical, physiologic, inflammatory, and comorbidity factors associated with EPA. METHODS: Baseline data from the NHLBI Severe Asthma Research Program (SARP)-3 were analyzed. An exacerbation was defined as a burst of systemic corticosteroids lasting 3 days or more. Patients were classified by their number of exacerbations in the past year: none, few (one to two), or exacerbation prone (≥3). Replication of a multivariable model was performed with data from the SARP-1 + 2 cohort. MEASUREMENTS AND MAIN RESULTS: Of 709 subjects in the SARP-3 cohort, 294 (41%) had no exacerbations and 173 (24%) were exacerbation prone in the prior year. Several factors normally associated with severity (asthma duration, age, sex, race, and socioeconomic status) did not associate with exacerbation frequency in SARP-3; bronchodilator responsiveness also discriminated exacerbation proneness from asthma severity. In the SARP-3 multivariable model, blood eosinophils, body mass index, and bronchodilator responsiveness were positively associated with exacerbation frequency (rate ratios [95% confidence interval], 1.6 [1.2-2.1] for every log unit of eosinophils, 1.3 [1.1-1.4] for every 10 body mass index units, and 1.2 [1.1-1.4] for every 10% increase in bronchodilatory responsiveness). Chronic sinusitis and gastroesophageal reflux were also associated with exacerbation frequency (1.7 [1.4-2.1] and 1.6 [1.3-2.0]), even after adjustment for multiple factors. These effects were replicated in the SARP-1 + 2 multivariable model. CONCLUSIONS: EPA may be a distinct susceptibility phenotype with implications for the targeting of exacerbation prevention strategies. Clinical trial registered with www.clinicaltrials.gov (NCT 01760915).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00080312 · Cited by 5,919
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926 · cited 1×
“Consistent with the 2012 definition of severe asthma (19), asthma control and risk were evaluated by the Asthma Control”
Self-citationSusceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Self-citationIdentification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Self-citationLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
Self-citationExploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Self-citationBlood eosinophil count and prospective annual asthma disease burden: a UK cohort study
Price, D. B., Rigazio, A., Campbell, J. D., Bleecker, E. R., Corrigan, C. J., Thomas, M., Wenzel, S. E., Wilson, A. M., Small, M. B., Gopalan, G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00367-7 · Cited by 591
Self-citationRisk factors of frequent exacerbations in difficult-to-treat asthma
ten Brinke, A., Sterk, P. J., Masclee, A. A. M., Spinhoven, P., Schmidt, J. T., Zwinderman, A. H., Rabe, K. F., & Bel, E. H. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00037905 · Cited by 490
Exacerbations of Asthma: A Descriptive Study of 425 Severe Exacerbations
TATTERSFIELD, A. E., POSTMA, D. S., BARNES, P. J., SVENSSON, K., BAUER, C.-A., O'BYRNE, P. M., LÖFDAHL, C.-G., PAUWELS, R. A., & ULLMAN, A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9811100 · Cited by 386
Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806290 · Cited by 382
The role of viruses in acute exacerbations of asthma
Jackson, D. J., & Johnston, S. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.021 · Cited by 351 · cited 3×
“001 Daily OCS, n (%) (past 3 mo),* CS 4 (1) 23 (10) 51 (30) ,0.”
Recent asthma exacerbations: A key predictor of future exacerbations
Miller, M. K., Lee, J. H., Miller, D. P., & Wenzel, S. E. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2006.07.005 · Cited by 288
Self-citationDolan, C. M., Fraher, K. E., Bleecker, E. R., Borish, L., Chipps, B., Hayden, M. L., Weiss, S., Zheng, B., Johnson, C., & Wenzel, S. (2004) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61707-3 · Cited by 287
Self-citationMalinovschi, A., Fonseca, J. A., Jacinto, T., Alving, K., & Janson, C. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.007 · Cited by 268
Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled Trial
Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook, J. T., Wise, R. A., Gold, B. D., Blake, K., Brown, E. D., Castro, M., Dozor, A. J., Lima, J. J., Mastronarde, J. G., et al. (2012) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.2011.2035 · Cited by 244
Self-citationVEEN, J. C. C. M. I., BEEKMAN, A. J., BEL, E. H., & STERK, P. J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.6.9906075 · Cited by 235
Mortality in Patients Hospitalized for Asthma Exacerbations in the United States
Krishnan, V., Diette, G. B., Rand, C. S., Bilderback, A. L., Merriman, B., Hansel, N. N., & Krishnan, J. A. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200601-007oc · Cited by 220
Frequent exacerbators – a distinct phenotype of severe asthma
Kupczyk, M., ten Brinke, A., Sterk, P. J., Bel, E. H., Papi, A., Chanez, P., Nizankowska‐Mogilnicka, E., Gjomarkaj, M., Gaga, M., Brusselle, G., et al. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12179 · Cited by 163
Asthma Exacerbations in North American Adults
Griswold, S., Nordstrom, C. R., Clark, S., Gaeta, T. J., Price, M. L., & Camargo, C. A. (2005) · CHEST Journal · doi:10.1378/chest.127.5.1579 · Cited by 136
Amar, Y. G., Frenkiel, S., & Sobol, S. E. (2000) · PubMed · Cited by 98
Loymans, R. J. B., Honkoop, P., Termeer, E. H., Snoeck-Stroband, J. B., Assendelft, W. J., Schermer, T. R., Chung, K. F., Sousa, A. R., Sterk, P. J., Reddel, H. K., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-208138 · Cited by 94
Prognostic value of cluster analysis of severe asthma phenotypes
BOURDIN, A. A., Molinari, N., Vachier, I., Varrin, M., Marin, G., Gamez, A. S., Paganin, F., & Chanez, P. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.038 · Cited by 76
Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease Control
Busse, W. W., Holgate, S. T., Wenzel, S. E., Klekotka, P. A., Chon, Y., Feng, J., Ingenito, E. P., & Nirula, A. (2015) · CHEST Journal · doi:10.1378/chest.14-2457 · Cited by 73
Self-citationCharacterisation of patients with frequent exacerbation of asthma
Koga, T., Oshita, Y., Kamimura, T., Koga, H., & Aizawa, H. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.05.017 · Cited by 68
Improved Criterion for Assessing Lung Function Reversibility
Ward, H., Cooper, B. G., & Miller, M. R. (2015) · CHEST Journal · doi:10.1378/chest.14-2413 · Cited by 64
Konno, A., Hoshino, T., & Togawa, K. (1980) · The Laryngoscope · doi:10.1288/00005537-198010000-00016 · Cited by 48
Surgical Treatment of Aspirin Triad Sinusitis
McFadden, E. A., Woodson, B. T., Fink, J. N., & Toohill, R. J. (1997) · American Journal of Rhinology · doi:10.2500/105065897781446702 · Cited by 44
Ayres, J. G., & Miles, J. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09051073 · Cited by 42
Dupilumab in Persistent Asthma
Wenzel, S. E., Wang, L., & Pirozzi, G. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1309809 · Cited by 35
Self-citation
Cited by
The basic immunology of asthma
Hammad, H., & Lambrecht, B. N. (2021) · Cell · doi:10.1016/j.cell.2021.02.016 · Cited by 1,105
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Self-citationInternational consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Bleecker, E. R., Menzies-Gow, A. N., Price, D. B., Bourdin, A., Sweet, S., Martin, A. L., Alacqua, M., & Tran, T. N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201904-0903so · Cited by 380
Self-citation
Metadata
- Authors
- Denlinger, L. C., Phillips, B. R., Ramratnam, S., Ross, K., Bhakta, N. R., Cardet, J. C., Castro, M., Peters, S. P., Phipatanakul, W., Aujla, S., Bacharier, L. B., Bleecker, E. R., Comhair, S. A. A., Coverstone, A., DeBoer, M., Erzurum, S. C., Fain, S. B., Fajt, M., Fitzpatrick, A. M., Gaffin, J., Gaston, B., Hastie, A. T., Hawkins, G. A., Holguin, F., Irani, A.-M., Israel, E., Levy, B. D., Ly, N., Meyers, D. A., Moore, W. C., Myers, R., Opina, M. T. D., Peters, M. C., Schiebler, M. L., Sorkness, R. L., Teague, W. G., Wenzel, S. E., Woodruff, P. G., Mauger, D. T., Fahy, J. V., & Jarjour, N. N.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-01
- Volume
- 195
- Issue
- 3
- Pages
- 302-313
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2517035143
- Cited by
- 435
- References
- 32
- FWCI
- 32.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.